NEXGEL Reports 31.5% Revenue Growth, Flags Going Concern, and Secures $56.67M Convertible Note Facility with Significant Dilution Potential

summarizeSummary

NEXGEL reported a 31.5% revenue increase for 2025 but disclosed a 'going concern' warning and material weaknesses in internal controls. The company secured a $56.67 million convertible note facility, with a large portion contingent on shareholder approval for a 10x increase in authorized shares and a reverse stock split, indicating significant potential dilution.

check_boxKey Events

• Annual Financial Results for Fiscal Year 2025

  NEXGEL reported net revenues of $11.42 million for the year ended December 31, 2025, a 31.5% increase from $8.69 million in 2024. The net loss attributable to stockholders decreased to $3.0 million in 2025 from $3.28 million in 2024. Operating cash flow improved significantly, with net cash used in operating activities reducing to $1.31 million in 2025 from $3.87 million in 2024.

• Going Concern Warning Issued

  Management and the independent auditors have raised substantial doubt about the company's ability to continue as a going concern due to recurring operating losses, negative cash flows, and insufficient cash resources to meet plans for the next twelve months. The cash balance as of December 31, 2025, was $317 thousand, excluding $741 thousand in restricted cash.

• Material Weaknesses in Internal Controls Identified

  Management concluded that internal control over financial reporting was not effective as of December 31, 2025, citing material weaknesses related to a lack of proper segregation of duties and a single individual having 'super user' access and security administration rights to financial reporting systems.

• $56.67 Million Convertible Note Facility Secured

  On February 9, 2026, NEXGEL entered into a Securities Purchase Agreement for a convertible note facility of up to $56.67 million. This includes $1.80 million in Series A Convertible Notes issued on February 10, 2026, with a conversion price of $1.244 per share (or an alternate conversion price at 95% of VWAP, floor $0.2488). An additional $54.87 million in Series B Convertible Notes is contingent on shareholder approval for a 10x increase in authorized shares (from 25M to 250M) and a reverse stock split (up to 250-to-1).

auto_awesomeAnalysis

NEXGEL's annual report reveals a mixed financial picture with strong revenue growth but persistent operational losses and a critical 'going concern' warning from management and auditors. The company's ability to continue operations is dependent on securing additional capital. To address this, NEXGEL has entered into a substantial convertible note facility, which, while providing much-needed capital, carries significant potential for shareholder dilution. The Series B notes, in particular, are contingent on shareholder approval for a massive increase in authorized shares and a reverse stock split, indicating a challenging path forward for existing equity holders. The proposed Celularity acquisition, while a positive strategic move, is also dependent on securing this financing. Furthermore, the disclosure of material weaknesses in internal financial controls adds another layer of risk, highlighting operational deficiencies that need urgent remediation. Investors should weigh the positive revenue growth and strategic expansion against the severe liquidity concerns, the highly dilutive financing structure, and governance issues.